title: Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
abstract: Long-term efficacy of lanthanum carbonate on hyperphosphatemia was examined in multicenter dialysis patients. Outcome and efficacy after 2 years was investigated in 101 patients who had undergone lanthanum carbonate administration. Thirty-three cases dropped out by the 2-year point; patients undergoing at least 2 years of administration totaled 68. Reasons for dropping out were as follows: improvement of hyperphosphatemia, nine cases; changing hospitals, seven cases; medical complications, five cases; digestive symptoms, four cases; poor compliance, four cases; parathyroidectomy, two cases; death, two cases. The mean dosage was increased from initial daily dosage of 744 mg to 1266 mg after 1 year, and to 1246 mg after 2 years. Serum phosphate concentration decreased significantly from the initial 6.15 mg to 5.57 mg/dL after 1 year, and to 5.45 mg/dL after 2 years. Although a lowering trend was observed in corrected calcium levels, the difference was not significant. Parathyroid hormone was unchanged. Achievement rate of Japanese Society for Dialysis Therapy (JSDT) management target values for both phosphorus and calcium improved from 32.7% to 50.0% after 1 year, and to 56.5% after 2 years. Lanthanum carbonate is useful as a therapeutic tool for hyperphosphatemia over long durations.
authors.affiliation: Department of Nephrology, Musashino Red Cross Hospital, Tokyo, Japan. rando@musashino.jrc.or.jp
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Ando
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kimura
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Sato
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Iwamoto
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yoshizaki
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Chida
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ishida
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takayama
authors.forename: Kouei
authors.initials: K
authors.lastname: Yamada
authors.forename: Ken
authors.initials: K
authors.lastname: Tachibana
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ohtsuka
authors.forename: Kan
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Inoue
mesh_terms: D000368:Aged; D002118:Calcium / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000628:therapy*; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; C119467:lanthanum carbonate; D007811:Lanthanum; D002118:Calcium